NCT06851806View on ClinicalTrials.gov

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

NANot yet recruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Respiratory Syncytial Virus (RSV)
Interventions
DRUG

Palivizumab 15 mg/kg

Single-dose liquid solution vials, 50 mg/0.5 mL, IM injection

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY